Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Naïve Patients

RATIONALE & OBJECTIVE: Prespecified analyses of the PRO(2)TECT trials comparing the safety of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat with darbepoetin alfa in patients with non–dialysis-dependent chronic kidney disease (NDD-CKD) found no difference in major adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkelmayer, Wolfgang C., Arnold, Susan, Burke, Steven K., Chertow, Glenn M., Eckardt, Kai-Uwe, Jardine, Alan G., Lewis, Eldrin F., Luo, Wenli, Matsushita, Kunihiro, McCullough, Peter A., Minga, Todd, Parfrey, Patrick S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329162/
https://www.ncbi.nlm.nih.gov/pubmed/37427293
http://dx.doi.org/10.1016/j.xkme.2023.100666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329162/
https://www.ncbi.nlm.nih.gov/pubmed/37427293
http://dx.doi.org/10.1016/j.xkme.2023.100666

Ejemplares similares